Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer

被引:12
作者
Belani, C. P.
Dakhil, S.
Waterhouse, D. M.
Desch, C. E.
Rooney, D. K.
Clark, R. H.
Monberg, M. J.
Ye, Z.
Obasaju, C. K.
机构
[1] Univ Pittsburgh, Inst Canc, Lung & Thorac Ctr Program, Pittsburgh, PA 15213 USA
[2] Canc Ctr Kansas PA, Wichita, KS USA
[3] Jewish Hosp Kenwood, Cincinnati, OH USA
[4] Hematol & Oncol Virginia, Richmond, VA USA
[5] Hematol Oncol Inc, Canton, OH USA
[6] Hematol Oncol Associates, Jackson, MI USA
[7] Lilly Res Labs, Indianapolis, IN USA
关键词
gemcitabine; non-platinum doublets; non-small-cell lung cancer; paclitaxel;
D O I
10.1093/annonc/mdl344
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Gemcitabine and paclitaxel (Taxol) each provides an efficacious non-platinum option for the treatment of advanced non-small-cell lung cancer (NSCLC), but the optimal dosage and schedule of the two agents used in combination are not well defined. Methods: Previously untreated patients with advanced NSCLC were randomized to receive gemcitabine-paclitaxel on a traditional three-weekly schedule (Arm A) or a novel weekly schedule (Arm B) as follows-Arm A (three-weekly): gemcitabine 1000 mg/m(2) infused > 30 min on days 1 and 8 and paclitaxel 200 mg/m(2) infused > 3 h on day 1 of a 21-day cycle or Arm B (weekly): gemcitabine 1000 mg/m(2) infused > 30 min and paclitaxel 100 mg/m(2) infused > 1 h, both administered on days 1 and 8 of a 21-day cycle. Results: One hundred patients received at least one dose of treatment. The weekly schedule, Arm B, was more efficacious and less hematologically toxic than Arm A. Confirmed complete and partial response rates were 28.2% and 26.8%, respectively. Median survival was 10.3 months on Arm B and 7.9 months on Arm A (log-rank P = 0.10); 1- and 2-year survival rates also favor Arm B: 42.0% versus 34.0% and 18.0% versus 6.0%. Progression-free survival was 5.8 versus 4.8 months, again favoring Arm B (log-rank P = 0.06). There was a two-fold lower frequency of grade 3/4 hematologic events with Arm B as follows: neutropenia (16% versus 30%), thrombocytopenia (4% versus 8%), and anemia (2% versus 6%). One patient (2%) in each treatment group developed febrile neutropenia. Conclusion: In this trial, both schedules were efficacious and tolerable, although the weekly schedule resulted in improved survival and lower hematologic toxicity compared with a three-weekly schedule. The weekly schedule of gemcitabine-paclitaxel indicates an improved therapeutic index.
引用
收藏
页码:110 / 115
页数:6
相关论文
共 34 条
[1]   EFFICACY AND SAFETY PROFILE OF GEMCITABINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ABRATT, RP ;
BEZWODA, WR ;
FALKSON, G ;
GOEDHALS, L ;
HACKING, D ;
RUGG, TA .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1535-1540
[2]   Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer [J].
Abratt, RP ;
Bezwoda, WR ;
Goedhals, L ;
Hacking, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :744-749
[3]   A Phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma [J].
Akerley, W ;
Rathore, R ;
Ready, N ;
Leone, L ;
Sikov, W ;
Safran, H ;
Kennedy, T .
CANCER, 2002, 95 (09) :2000-2005
[4]   Paclitaxel in advanced non-small cell lung cancer - An alternative high-dose weekly schedule [J].
Akerley, W .
CHEST, 2000, 117 (04) :152S-155S
[5]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[6]  
American Cancer Society, 2005, CANC FACTS FIG 2005
[7]   SINGLE-AGENT ACTIVITY OF WEEKLY GEMCITABINE IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ANDERSON, H ;
LUND, B ;
BACH, F ;
THATCHER, N ;
WALLING, J ;
HANSEN, HH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1821-1826
[8]  
[Anonymous], CANC FACTS FIG 2004
[9]   Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation [J].
Belani, CP ;
Barstis, J ;
Perry, MC ;
La Rocca, RV ;
Nattam, SR ;
Rinaldi, D ;
Clark, R ;
Mills, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2933-2939
[10]   A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer [J].
Bhatia, S ;
Hanna, N ;
Ansari, R ;
Pletcher, W ;
Einhorn, L ;
Ng, E ;
Sandler, A .
LUNG CANCER, 2002, 38 (01) :73-77